PTC Therapeutics (NASDAQ: PTCT) director sells 6,333 shares at $63.38

Rhea-AI Filing Summary

PTC Therapeutics, Inc. director Stephanie Okey sold 6,333 shares of common stock in an open-market transaction on March 5, 2026 at $63.38 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After this transaction, she directly holds 8,000 PTC Therapeutics shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		6,333	D	$63.38	8,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report for Stephanie Okey?

PTC Therapeutics reported that director Stephanie Okey sold 6,333 shares of common stock. The transaction was an open-market sale executed on March 5, 2026, according to a Form 4 insider trading report.

At what price did Stephanie Okey sell PTC Therapeutics (PTCT) shares?

Stephanie Okey sold PTC Therapeutics common stock at $63.38 per share. The Form 4 filing notes this as the transaction price for the 6,333 shares sold in an open-market sale on March 5, 2026.

How many PTC Therapeutics (PTCT) shares does Stephanie Okey hold after the sale?

After the reported sale, Stephanie Okey directly holds 8,000 shares of PTC Therapeutics common stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects her direct holdings following the March 5, 2026 sale.

Was the PTC Therapeutics (PTCT) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was effected under a written Rule 10b5-1 trading plan. That plan was adopted by Stephanie Okey on November 24, 2025, indicating the sale was pre-arranged rather than opportunistic.

What type of transaction did PTC Therapeutics (PTCT) disclose for Stephanie Okey?

The company disclosed an open-market sale of common stock by director Stephanie Okey. The Form 4 identifies the transaction code as “S”, described as a sale in an open market or private transaction involving 6,333 shares.